高剂量泊沙康唑对血液恶性肿瘤成年患者血清水平的影响。
Effect of High-Dose Posaconazole on Serum Levels in Adult Patients with Hematologic Malignancy.
机构信息
Division of Pharmacy, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
Department of Infectious Diseases and Employee Health, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0123021. doi: 10.1128/AAC.01230-21. Epub 2021 Sep 27.
Abstract
Posaconazole (POS) appears to have dose-proportional pharmacokinetics; however, there is a paucity of real-life data. We retrospectively evaluated 67 patients with hematologic cancer who had POS dose increases from 300 mg/day to either 400 mg/day ( = 52) or 300 mg twice daily (BID) ( = 15) and for whom POS serum levels were measured. Median POS levels were 840 ng/ml, 1,625 ng/ml, and 2,710 ng/ml for the dosages of 300 mg/day, 400 mg/day, and 300 mg BID, respectively. Significant interpatient variability in serum levels was noted.
摘要
泊沙康唑（POS）的药代动力学似乎呈剂量比例关系，但实际数据较少。我们回顾性评估了 67 例血液系统恶性肿瘤患者，这些患者的泊沙康唑剂量从 300mg/天增加到 400mg/天（ = 52）或 300mg 每日两次（BID）（ = 15），并对这些患者的泊沙康唑血清水平进行了检测。300mg/天、400mg/天和 300mg BID 的泊沙康唑血清水平中位数分别为 840ng/ml、1625ng/ml和 2710ng/ml。观察到血清水平存在显著的个体间变异性。
相似文献
1
Effect of High-Dose Posaconazole on Serum Levels in Adult Patients with Hematologic Malignancy.高剂量泊沙康唑对血液恶性肿瘤成年患者血清水平的影响。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0123021. doi: 10.1128/AAC.01230-21. Epub 2021 Sep 27.
2
Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.通过对343个疗程的分析，对泊沙康唑新片剂和静脉制剂预防侵袭性真菌感染的安全性和有效性进行实际评估
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00188-17. Print 2017 Aug.
3
Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.与泊沙康唑混悬剂相比，泊沙康唑片治疗并未降低泊沙康唑谷浓度的变异性。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00484-19. Print 2019 Oct.
4
A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.一项评估泊沙康唑口服混悬液在中性粒细胞减少的免疫功能低下儿童中的安全性、耐受性和药代动力学的非随机试验。
PLoS One. 2019 Mar 26;14(3):e0212837. doi: 10.1371/journal.pone.0212837. eCollection 2019.
5
Posaconazole liquid vs tablet formulation in lung transplant recipients.泊沙康唑口服液与片剂在肺移植受者中的应用。
Mycoses. 2018 Mar;61(3):186-194. doi: 10.1111/myc.12724. Epub 2017 Nov 22.
6
Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.泊沙康唑静脉制剂和口服制剂在抗真菌治疗和预防中的应用：一项回顾性、非干预性、多中心分析，纳入了在三级医院接受治疗的血液科患者。
Int J Infect Dis. 2019 Jun;83:130-138. doi: 10.1016/j.ijid.2019.04.006. Epub 2019 Apr 9.
7
Effectiveness of increasing the frequency of posaconazole syrup administration to achieve optimal plasma concentrations in patients with haematological malignancy.提高泊沙康唑糖浆给药频率以实现血液恶性肿瘤患者最佳血药浓度的效果。
Int J Antimicrob Agents. 2016 Jul;48(1):106-110. doi: 10.1016/j.ijantimicag.2016.04.013. Epub 2016 May 12.
8
Posaconazole delayed-release tablets in paediatric haematology-oncology patients.泊沙康唑延迟释放片在儿科血液肿瘤患者中的应用。
Mycoses. 2020 Jun;63(6):604-609. doi: 10.1111/myc.13084. Epub 2020 Apr 15.
9
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.泊沙康唑片剂在侵袭性真菌病高危患者中的3期药代动力学和安全性研究。
J Antimicrob Chemother. 2016 Mar;71(3):718-26. doi: 10.1093/jac/dkv380. Epub 2015 Nov 26.
10
Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies.泊沙康唑口服混悬液在血液系统恶性肿瘤患者中的早期治疗药物监测
Ther Drug Monit. 2018 Feb;40(1):115-119. doi: 10.1097/FTD.0000000000000469.
引用本文的文献
1
Real-world Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels.泊沙康唑在肿瘤患者中治疗药物监测的真实世界经验：低白蛋白血症作为泊沙康唑治疗水平不足预测指标的临床意义
Open Forum Infect Dis. 2024 Mar 29;11(5):ofae185. doi: 10.1093/ofid/ofae185. eCollection 2024 May.
本文引用的文献
1
High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.高剂量泊沙康唑治疗唑类耐药曲霉菌病和其他难治疗的霉菌感染。
Mycoses. 2020 Feb;63(2):122-130. doi: 10.1111/myc.13028. Epub 2019 Dec 15.
2
Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension.使用状态转换模型探讨亚治疗性泊沙康唑暴露的患病率如何影响泊沙康唑片剂和口服混悬液治疗药物监测的临床效用。
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01435-19. Epub 2019 Sep 16.
3
Risk factors for subtherapeutic levels of posaconazole tablet.泊沙康唑片治疗浓度不足的危险因素。
J Antimicrob Chemother. 2017 Oct 1;72(10):2902-2905. doi: 10.1093/jac/dkx228.
4
Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.对急性髓系白血病患者在转换为泊沙康唑片剂制剂前后预防侵袭性真菌感染时达到目标药物水平情况的回顾性分析。
J Oncol Pharm Pract. 2018 Dec;24(8):599-603. doi: 10.1177/1078155217722405. Epub 2017 Aug 2.
5
Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.通过对343个疗程的分析，对泊沙康唑新片剂和静脉制剂预防侵袭性真菌感染的安全性和有效性进行实际评估
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00188-17. Print 2017 Aug.
6
Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation.泊沙康唑缓释片血清水平及其与肝毒性和QTc延长相关性的多中心研究。
J Antimicrob Chemother. 2017 Aug 1;72(8):2355-2358. doi: 10.1093/jac/dkx122.
7
Antifungal agents and liver toxicity: a complex interaction.抗真菌药物与肝毒性：一种复杂的相互作用。
Expert Rev Anti Infect Ther. 2016 Aug;14(8):765-76. doi: 10.1080/14787210.2016.1199272. Epub 2016 Jun 23.
8
Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.泊沙康唑的血浆暴露量与异基因干细胞移植患者的肠道粘膜炎相关。
Eur J Clin Pharmacol. 2016 Aug;72(8):953-63. doi: 10.1007/s00228-016-2057-6. Epub 2016 Apr 11.
9
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.泊沙康唑片剂在侵袭性真菌病高危患者中的3期药代动力学和安全性研究。
J Antimicrob Chemother. 2016 Mar;71(3):718-26. doi: 10.1093/jac/dkv380. Epub 2015 Nov 26.
10
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.泊沙康唑在侵袭性肺曲霉病和毛霉病中性粒细胞减少小鼠模型中的比较药效学。
Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.
Zotero 插件